Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | COMT | P21964 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | OXTR | P30559 | 2/20 | 0.31 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 3/20 | 0.31 |
| ▸ | LATS1 | O95835 | 1/20 | 0.30 |
| ▸ | LATS2 | Q9NRM7 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 2/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15372303 | 0.81 | OXTR (0.36) | COMTHTTOXTRAVPR1ACYP1A2 | |
| SCHEMBL19857578 | 0.81 | COMT (0.35) | COMTHTTCYP1A2CYP2D6CYP2C19 | |
| SCHEMBL22071582 | 0.81 | COMT (0.35) | COMTHTTOXTRAVPR1AALDH1A1 | |
| SCHEMBL18857343 | 0.81 | COMT (0.35) | COMTHTT | |
| SCHEMBL173343 | 0.78 | OXTR (0.40) | COMTHTTOXTRAVPR1ACYP1A2 | |
| SCHEMBL16962898 | 0.76 | OXTR (0.36) | COMTHTTOXTRAVPR1ACYP1A2 | |
| SCHEMBL5000984 | 0.76 | COMT (0.32) | COMTCYP19A1KMT2AL3MBTL1 | |
| SCHEMBL18935615 | 0.74 | CYP1A2 (0.36) | COMTCYP1A2CYP2D6CYP2C19CYP3A4 | |
| SCHEMBL6762492 | 0.73 | DRD1 (0.31) | CYP1A2CYP2D6CYP2C19CYP3A4KMT2A | |
| SCHEMBL9944599 | 0.73 | ALDH1A1 (0.31) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 310 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017133701-A1 | CERTAIN PROTEIN KINASE INHIBITORS | SHANGHAI FOCHON PHARMACEUTICAL CO., LTD. (CN) | 2017-08-10 | — | — | WO | claimed |
| US-20240239809-A1 | THERAPEUTIC AGENTS FOR ENHANCING EPITHELIAL AND/OR ENDOTHELIAL BARRIER FUNCTION | ARTUS THERAPEUTICS INC (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240238296-A1 | METHODS OF REGULATING BCL11A EXPRESSION AND TREATMENT OF BCL11A-MEDIATED DISORDERS | FULCRUM THERAPEUTICS INC (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240238296-A1 | METHODS OF REGULATING BCL11A EXPRESSION AND TREATMENT OF BCL11A-MEDIATED DISORDERS | FULCRUM THERAPEUTICS INC (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240228484-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-11 | — | — | US | disclosed |
| US-12024500-B2 | Five-membered ring-substituted pyridazinol compounds and derivatives, preparation methods, herbicidal compositions and applications thereof | QINGDAO KINGAGROOT CHEMICAL COMPOUND CO., LTD. (CN) | 2024-07-02 | — | — | US | disclosed |
| US-20240067641-A1 | INHIBITORS OF TRIM33 AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-02-29 | — | — | US | disclosed |
| US-20240067641-A1 | INHIBITORS OF TRIM33 AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-02-29 | — | — | US | disclosed |
| EP-4289833-A1 | TYK2 INHIBITOR COMPOUND CONTAINING BICYCLIC RING | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-12-13 | — | — | EP | disclosed |
| US-11820770-B2 | P2X7 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| US-20080108626-A1 | (5-amino-1-phenyl-1H-pyrazole)-(3-Amino-N-isoxazol-3-yl-4-methyl)-benzamide; p38 mitogen-activated protein kinase inhibitor; reduced levels of TNF- alpha expression; antiinfammatory agent: rheumatoid arthritis, psoriasis, multiple sclerosis, endotoxin shock, osteoporosis, Alzheimer's disease | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-08 | — | — | US | disclosed |
| US-20080064718-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC. (CA) | 2008-03-13 | — | — | US | disclosed |
| US-20080039504-A1 | TRIAZOLYL PYRIDYL BENZENESULFONAMIDES | CHEMOCENTRYX, INC. | 2008-02-14 | — | — | US | disclosed |
| US-20080039504-A1 | TRIAZOLYL PYRIDYL BENZENESULFONAMIDES | CHEMOCENTRYX, INC. | 2008-02-14 | — | — | US | disclosed |
| US-20080004273-A1 | Inhibitors of protein tyrosine kinase activity | METHYLGENE, INC. (CA) | 2008-01-03 | — | — | US | disclosed |
| US-20080004273-A1 | Inhibitors of protein tyrosine kinase activity | METHYLGENE, INC. (CA) | 2008-01-03 | — | — | US | disclosed |
| US-7253167-B2 | Tricyclic-heteroaryl compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-08-07 | — | — | US | disclosed |
| US-20070149534-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-28 | — | — | US | disclosed |
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE, INC. | 2007-01-04 | — | — | US | disclosed |
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE, INC. | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12024500-B2 | Five-membered ring-substituted pyridazinol compounds and derivatives, preparation methods, herbicidal compositions and applications thereof | DDT, CYP3A5, CYP4B1 | COMT 1475/4885HTT 2307/4885OXTR 1978/4885 |
| US-20080039504-A1 | TRIAZOLYL PYRIDYL BENZENESULFONAMIDES | CCR9, CCR2, CCR1 | COMT 4796/4885HTT 3160/4885OXTR 2092/4885 |
| US-20240228484-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, PNLIP | COMT 893/4885HTT 3524/4885OXTR 375/4885 |
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | HGF, MET, FLT1 | COMT 2540/4885HTT 572/4885OXTR 1000/4885 |
| US-20240238296-A1 | METHODS OF REGULATING BCL11A EXPRESSION AND TREATMENT OF BCL11A-MEDIATED DISORDERS | BCLAF1, EED, BCL3 | COMT 3236/4885HTT 3538/4885OXTR 3829/4885 |
| US-20080108626-A1 | (5-amino-1-phenyl-1H-pyrazole)-(3-Amino-N-isoxazol-3-yl-4-methyl)-benzamide; p38 mitogen-activated protein kinase inhibitor; reduced levels of TNF- alpha expression; antiinfammatory agent: rheumatoid arthritis, psoriasis, multiple sclerosis, endotoxin shock, osteoporosis, Alzheimer's disease | MAPK1, MAPK3, TNF | COMT 4048/4885HTT 3903/4885OXTR 2486/4885 |
| US-20080064718-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | HGF, ERBB2, MET | COMT 1375/4885HTT 566/4885OXTR 3354/4885 |
| US-20240239809-A1 | THERAPEUTIC AGENTS FOR ENHANCING EPITHELIAL AND/OR ENDOTHELIAL BARRIER FUNCTION | LIPG, FABP2, EPCAM | COMT 4022/4885HTT 4527/4885OXTR 2502/4885 |
| US-20240067641-A1 | INHIBITORS OF TRIM33 AND METHODS OF USE | TRIM33, TRIM28, TRIM4 | COMT 2858/4885HTT 1552/4885OXTR 4813/4885 |
| US-20070149534-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | NTRK2, NTRK3, NTRK1 | COMT 1368/4885HTT 1628/4885OXTR 1391/4885 |
| US-11820770-B2 | P2X7 modulators | P2RX2, P2RX7, P2RY2 | COMT 3869/4885HTT 2817/4885OXTR 1134/4885 |
| US-20080004273-A1 | Inhibitors of protein tyrosine kinase activity | HGF, ERBB2, MET | COMT 1375/4885HTT 566/4885OXTR 3354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.